Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.
J. S. Kovach, Arndt Hartmann, Hagen Blaszyk et al. · Proceedings of the National Academy of Sciences · 1996
Human cancer cells with a mutated p53 tumor-suppressor gene have a selective growth advantage and may exhibit resistance to ionizing radiation and certain chemotherapeutic agents. To examine the prognostic value of mutations in the p53 gene, a cohort of 90 Midwestern Caucasian breast cancer patients were analyzed with methodology that detects virtually 100% of all mutations. The presence of a p53 gene mutation was by far the single most predictive indicator for recurrence and death (relative risks of 4.7 and 23.2, respectively). Direct detection of p53 mutations had substantially greater prognostic value than immunohistochemical detection of p53 overexpression. Analysis of p53 gene mutations may permit identification of a subset of breast cancer patients who, despite lack of conventional indicators of poor prognosis, are at high risk of early recurrence and death.
Cited by 127 works. doi:10.1073/pnas.93.3.1093
Authors
References
- p53 Mutations in Human Cancers
- p53, guardian of the genome
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
- Genomic Amplification with Transcript Sequencing
- p53 Status and the Efficacy of Cancer Therapy in Vivo
- Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment
- A comparison of the biological activities of wild‐type and mutant p53
- Scanning from an independently specified branch point defines the 3′ splice site of mammalian introns
- Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
- Dideoxy fingerprinting (ddF): A rapid and efficient screen for the presence of mutations